Gallbladder cancer in South America: epidemiology and prevention.

Chin Clin Oncol

ILOGI (Latin-American Gastrointestinal Oncology Intergroup), San Salvador de Jujuy, Argentina.

Published: August 2019

The incidence and the mortality of gallbladder cancer (GBC) show significant variation worldwide, with high age-standardized rates in western South America (SA). Due to the lack of effective measures for prevention, the late diagnosis and the small benefit of systemic treatment, GBC has an ominous prognosis and became an important public health problem in this part of the continent, where the most important risk factors are gallstone disease, female gender, age, ethnic groups, and low socioeconomic status. Many genetic abnormalities have been described in series from SA, some of them similar and others unique in comparison to gene alterations in GBC from other regions of the world. Prophylactic cholecystectomy (PC) is one of the strategies to decrease the mortality but its cost-effectiveness is questionable. A way to improve the performance of PC is to identify molecular risk factors that in combination with currently known ones detect patients with very high risk for developing GBC. Also, more research studies are required to better understand the epidemiology and molecular biology in order to improve the prevention and treatment of this lethal disease.

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2019.07.12DOI Listing

Publication Analysis

Top Keywords

gallbladder cancer
8
south america
8
risk factors
8
cancer south
4
america epidemiology
4
epidemiology prevention
4
prevention incidence
4
incidence mortality
4
mortality gallbladder
4
gbc
4

Similar Publications

Gallbladder cancer (GBC) is an aggressive malignancy with a poor prognosis, often diagnosed at advanced stages due to subtle early symptoms. Recent studies have provided a comprehensive view of GBC's genetic and mutational landscape, uncovering crucial pathways involved in its pathogenesis. Environmental exposures, particularly to heavy metals, have been linked to elevated GBC risk.

View Article and Find Full Text PDF

Objective: This study was aimed at ascertaining the application value of abnormal prothrombin (PIVKA-II) and carbohydrate antigen 125 (CA125) in gallbladder cancer (GBC) diagnosis.

Methods: A total of 70 GBC patients, 70 patients with benign gallbladder diseases (gallbladder stones and gallbladder polyps), and 70 normal health examination people were selected as the malignant, benign, and normal groups, respectively. The differences in serum levels and positive rates of PIVKA-II and CA125 were compared.

View Article and Find Full Text PDF

Global Burden, Trends, and Inequalities of Gallbladder and Biliary Tract Cancer, 1990-2021: A Decomposition and Age-Period-Cohort Analysis.

Liver Int

February 2025

Department of Pancreatobiliary Surgery, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.

Article Synopsis
  • Gallbladder and biliary tract cancer (GBTC) is a rising global health issue, with 216,768 new cases and significant related deaths and disability-adjusted life years (DALYs) lost in 2021.
  • From 1990 to 2021, while the age-standardized rates (ASR) of GBTC incidence and mortality have slightly decreased overall, there are gender and regional disparities; males show a slight increase in incidence, while females see a significant decline.
  • Future projections suggest a gradual decline in the global burden of GBTC, particularly among females, although populations in low and low-middle sociodemographic index (SDI) regions are experiencing rising metrics despite lower absolute
View Article and Find Full Text PDF

Modification of gemcitabine with oxaliplatin in China for unresectable gallbladder cancer: a cost-effectiveness analysis.

Front Public Health

December 2024

Department of Pharmacy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Background: The incidence of gall bladder cancer (GBC), one of the most prevalent bile duct malignancies, differs with ethnicity and geographic location. To treat unresected GBC in the Chinese setting, this study aimed to assess the financial effectiveness of a combination of modified gemcitabine and oxaliplatin.

Methods: Data from a randomized controlled study in which individuals with metastatic GBC were treated with oxaliplatin and gemcitabine demonstrated improved survival.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!